The company has received the EIR from the US drug regulator on successful inspection closure. Image source: Reuters
Orchid Pharma today said it has received Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its Chennai facility.
The company has received the EIR from the US drug regulator on successful inspection closure.
According to the BSE filing, the regulator conducted the post-marketing adverse drug experience reporting inspection (PADE) at Nungambakkam, Chennai facility.
The company's stock closed 4.93% up on the BSE today.
By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.